The short answer
Leptin is a hormone secreted by fat tissue that signals how much energy is stored. Its 1995 characterisation produced some of the most dramatic weight results ever published in animals, and the same paper contained the finding that explains why it failed as an obesity drug.
Key facts
- Source
- Adipose tissue; the product of the ob gene
- Size
- 16 kilodalton protein
- Signal carried
- Magnitude of stored energy
- ob/ob mice
- No detectable circulating protein
- db/db mice
- Elevated levels, no response
- Effect in ob/ob mice
- 30% body weight reduction in 2 weeks
- Effect in wild-type mice
- 12% weight loss; body fat 12.2% to 0.7%
- Licensed form
- Metreleptin, for generalised lipodystrophy, not obesity
Why 1995 looked like the end of the problem
Halaas and colleagues showed that the product of the ob locus was present as a 16 kilodalton protein in mouse and human plasma and was undetectable in the plasma of ob/ob mice, the strain that becomes massively obese. Daily injections of recombinant protein reduced the body weight of ob/ob mice by 30 percent in two weeks with no apparent toxicity, reducing food intake and increasing energy expenditure. The result in normal animals was more startling still: wild-type mice injected twice daily lost 12 percent of body weight and their body fat fell from 12.2 percent to 0.7 percent. A hormone that takes a normal animal to almost no fat reserve is not a modest finding, and the reaction at the time was correspondingly large.
The result in the same paper that predicted the failure
Two sentences in that paper contain the entire subsequent history of leptin as a drug. Plasma levels of the protein were increased in db/db mice, a strain thought to be resistant to the effects of ob, and the injected protein had no effect on those animals. A mutant with high circulating hormone and no response to more of it is the definition of resistance. Common human obesity turned out to resemble db/db far more than ob/ob: people with obesity generally have high circulating leptin, in proportion to fat mass, and giving them more produces little. The hormone reports how much fat is stored, and in obesity that report is being made loudly and ignored.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What leptin is actually for
The framing that survives is that leptin is not a satiety signal but a starvation signal, and that its physiology is asymmetric. Falling leptin, as fat stores decline, triggers a powerful defensive response (increased hunger, reduced energy expenditure, altered reproductive and thyroid function), because from an evolutionary standpoint the emergency is not having too much stored energy but too little. Rising leptin produces a far weaker response in the other direction, because there was rarely any need for one. A system built to defend a floor does not have an equally capable ceiling, and that asymmetry is why supplying more of the signal does little.
Where leptin did become a medicine
Metreleptin, a recombinant leptin analogue, is licensed, but for generalised lipodystrophy, a rare condition in which adipose tissue is absent or severely deficient and circulating leptin is consequently very low. That is the human equivalent of ob/ob rather than of common obesity: the signal really is missing, so replacing it works. The same logic applies to the very rare cases of congenital leptin deficiency, where treatment is transformative. Leptin is an effective drug in populations defined by not having any, and an ineffective one in the far larger population that has plenty.
Why this history matters for reading current claims
Leptin is the cautionary case the whole field learned from, and its shape recurs. A hormone is identified; administering it to a deficient animal produces spectacular results; the deficiency turns out not to be the human problem; resistance or desensitisation blunts the response in the population that matters. GDF15's apparent susceptibility to desensitisation on prior exposure is a version of the same question. So is the observation that appetite-suppressing signals tend to run out of headroom. When a new appetite hormone is announced, the useful question is not whether it reduces intake in a deficient model but whether the human population is deficient in it.
What incretins did differently
GLP-1 receptor agonism did not succeed by replacing a missing hormone. It succeeded by administering a pharmacological exposure well above anything physiology produces, to a receptor that does not appear to develop the same resistance, sustained by engineering that keeps concentrations high for a week at a time. That is a different strategy from hormone replacement, and it is the reason the incretin class cleared an obstacle that stopped leptin, PYY and several others. Semaglutide and tirzepatide are licensed medicines and nothing supplied on this site is a version of or an alternative to either.
Quick reference
| ob/ob mice | db/db mice | Common human obesity | |
|---|---|---|---|
| Circulating leptin | Undetectable | Elevated | Elevated |
| Underlying defect | No hormone | Resistant to hormone | Largely resistant |
| Response to leptin | 30% weight loss in 2 weeks | None | Minimal |
| Analogous human condition | Congenital leptin deficiency | - | - |
Frequently asked questions
Does leptin cause weight loss in people?
Only in people who lack it: congenital leptin deficiency and generalised lipodystrophy, both rare. In common obesity, circulating leptin is already high and administering more has little effect.
What is leptin resistance?
A description of the observation that high circulating leptin coexists with the physiological state it should be suppressing. Whether it reflects impaired transport into the brain, receptor-level signalling changes, or something else is still argued, and calling it resistance names the phenomenon rather than explaining it.
Could leptin work in combination with something else?
That has been the main line of enquiry since, on the reasoning that lowering weight by other means may restore leptin sensitivity, or that a co-agent may address the resistance directly. It remains an open question rather than a demonstrated strategy.
Why did the body-fat figure fall to 0.7%?
Because those were normal lean mice given a large exogenous dose of a hormone whose signal they had no reason to resist, over two weeks. It is a demonstration of what the pathway can do when it is fully engaged in a responsive animal, and not a prediction of what happens in a resistant one.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Only Gut Hormone That Makes You Eat, and What Switches It OffGhrelin is the one circulating gut hormone that stimulates feeding. LEAP2, discovered in 2017, is its endogenous antagonist and moves in the opposite direction.
- There Is No Amylin Receptor GeneThe amylin receptor is not its own protein. It is the calcitonin receptor plus an accessory protein, and which accessory decides what the receptor recognises.
- Four Hormones, One Failure ModeLeptin, PYY, ghrelin and GDF15 all reduce or drive food intake in animals. None of them produced a weight-management drug, and the reasons they failed rhyme.
- Why the Same Gene Makes Glucagon in One Cell and GLP-1 in AnotherGlucagon, GLP-1, GLP-2, oxyntomodulin and glicentin all come from a single precursor. The textbook explanation of how a cell chooses between them is incomplete.
- The Other Peptide the L Cell ReleasesGLP-2 is co-secreted with GLP-1 from the very same cells and does something entirely different. Its analogue teduglutide is a licensed prescription medicine.